Fajgenbaum David C, Hayday Adrian C, Rogers Angela J, Towers Greg J, Wack Andreas, Zanoni Ivan
University of Pennsylvania.
King's College London; The Francis Crick Institute.
Fac Rev. 2022 Jun 10;11:15. doi: 10.12703/r-01-0000010. eCollection 2022.
COVID-19 ranges from asymptomatic through to respiratory failure and death. Although specific pre-existing conditions such as age and male sex have been associated with poor outcomes, we remain largely ignorant of the mechanisms predisposing to severe disease. In this study, the authors discovered that approximately 10% of 987 patients with life-threatening COVID-19 harbored neutralizing antibodies to Type I interferons (IFNs). They demonstrated that these antibodies could neutralize high concentrations of the corresponding IFN and could rescue SARS-CoV-2 infection from inhibition by IFN . Importantly, anti-IFN antibodies were associated with low levels of serum IFN. These observations suggest that disease severity in these individuals results from a failure to control SARS-CoV-2 replication because of antibody-mediated IFN inhibition. The study suggests specific treatments and diagnostics for this class of severe COVID-19.
新冠病毒病(COVID-19)的症状表现范围从无症状到呼吸衰竭及死亡。尽管诸如年龄和男性性别等特定的基础疾病已被发现与不良预后相关,但我们在很大程度上仍不清楚导致重症疾病的机制。在本研究中,作者发现,在987例危及生命的COVID-19患者中,约10%的患者体内存在针对I型干扰素(IFN)的中和抗体。他们证明,这些抗体能够中和高浓度的相应干扰素,并能使严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染免受干扰素的抑制。重要的是,抗干扰素抗体与血清干扰素水平较低有关。这些观察结果表明,这些个体的疾病严重程度是由于抗体介导的干扰素抑制导致无法控制SARS-CoV-2复制所致。该研究提示了针对这类重症COVID-19的特异性治疗方法和诊断手段。